Imperial College London
Alternate

Dr Peter Kelleher

Faculty of Medicine, Department of Infectious Disease

Reader in Immunology
 
 
 
//

Contact

 

+44 (0)20 3315 8251p.kelleher

 
 
//

Location

 

J.2.10Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Clarke:2020:10.1681/ASN.2020060827,
author = {Clarke, C and Prendecki, M and Dhutia, A and Ali, MA and Sajjad, H and Shivakumar, O and Lightstone, L and Kelleher, P and Pickering, MC and Thomas, D and Charif, R and Griffith, M and McAdoo, SP and Willicombe, M},
doi = {10.1681/ASN.2020060827},
journal = {Journal of the American Society of Nephrology},
pages = {1969--1975},
title = {High prevalence of asymptomatic COVID-19 infection in hemodialysis patients detected using serologic screening},
url = {http://dx.doi.org/10.1681/ASN.2020060827},
volume = {31},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Strategies to minimize the risk of transmission and acquisition of COVID-19 infection in patients with ESKD receiving in-center hemodialysis have been rapidly implemented across the globe. Despite these interventions, confirmed COVID-19 infection rates have been high in the United Kingdom. Prevalence of asymptomatic disease in an adult hemodialysis population has not been reported. Also, to our knowledge, the development of humoral response to SARS-CoV-2 has not been previously reported in this population. Although serologic testing does not provide information on the infectivity of patients, seroprevalence studies may enable investigation of exposure within dialysis units and hence, assessment of current screening strategies. METHODS: To investigate the seroprevalence of SARS-CoV-2 antibodies in a hemodialysis population, we used the Abbott IgG assay with the Architect system to test serum samples from 356 patients receiving in-center hemodialysis for SARS-CoV-2 antibodies. RESULTS: Of 356 patients, 121 had been symptomatic when screened before a dialysis session and received an RT-PCR test; 79 (22.2% of the total study population) tested positive for COVID-19. Serologic testing of all 356 patients found 129 (36.2%) who tested positive for SARS-CoV-2 antibodies. Only two patients with PCR-confirmed infection did not seroconvert. Of the 129 patients with SARS-CoV-2 antibodies, 52 (40.3%) had asymptomatic disease or undetected disease by PCR testing alone. CONCLUSIONS: We found a high seroprevalence of SARS-CoV-2 antibodies in patients receiving in-center hemodialysis. Serologic evidence of previous infection in asymptomatic or PCR-negative patients suggests that current diagnostic screening strategies may be limited in their ability to detect acute infection.
AU  - Clarke,C
AU  - Prendecki,M
AU  - Dhutia,A
AU  - Ali,MA
AU  - Sajjad,H
AU  - Shivakumar,O
AU  - Lightstone,L
AU  - Kelleher,P
AU  - Pickering,MC
AU  - Thomas,D
AU  - Charif,R
AU  - Griffith,M
AU  - McAdoo,SP
AU  - Willicombe,M
DO  - 10.1681/ASN.2020060827
EP  - 1975
PY  - 2020///
SN  - 1046-6673
SP  - 1969
TI  - High prevalence of asymptomatic COVID-19 infection in hemodialysis patients detected using serologic screening
T2  - Journal of the American Society of Nephrology
UR  - http://dx.doi.org/10.1681/ASN.2020060827
UR  - https://jasn.asnjournals.org/content/31/9/1969
UR  - http://hdl.handle.net/10044/1/81758
VL  - 31
ER  -
Download